Tenet Healthcare Corporation (THC) Up 8.3% — Time to Go All In on This Idea?
Tenet Healthcare Corporation (THC) is rallying on Wednesday, last trading at $288.77 on the NYSE, a $22.08 gain from the prior close of $266.69. The advance pushes the stock into record territory for the past year. THC is now trading roughly 2.0% above its previous 52-week high of $283.05, set on August 24, 2026. A stock clearing a level that capped it for more than two months is a stock with momentum, and Tenet has it.
Volume has already reached about 1.09 million shares with the session still open, ahead of the 90-day average of roughly 948,000. Buyers are showing up in force before the closing bell.
Why Tenet Healthcare Corporation Price is Moving Higher
The lead catalyst is political, and it lifted the entire Health Care sector. Democrats won control of both chambers of Congress in the midterm elections, and investors moved quickly into hospital operators. HCA Healthcare (HCA), Tenet, and Universal Health Services (UHS) were up roughly 6% to 8% in early trading. HCA has since extended that run to a 10.14% gain. The logic behind the rally is direct. A Democratic Congress could delay parts of the 2025 One Big Beautiful Bill, which was expected to reduce Medicaid enrollment and constrain some state hospital payments. It also improves the odds that Affordable Care Act subsidies get extended. Both outcomes would protect the insured patient base that hospital operators depend on for reimbursement.
The enthusiasm spread across Health Care sector. Medtronic plc (MDT) is up 6.61%, and distributors such as McKesson Corporation (MCK) are posting gains of nearly 4%. JPMorgan analysts noted that legislative gridlock makes sweeping policy changes unlikely. For hospital investors, though, a slower pace of Medicaid cuts is a meaningful win on its own, and today's buying reflects relief that the worst-case reimbursement scenario has become less likely.
Tenet came into the election with strong results behind it. On October 29, the company reported Q3 adjusted EPS of $6.64, well ahead of the $4.60 Zacks consensus and up 79.5% year over year. Revenue reached $5.63 billion against a $5.47 billion estimate, a 6.5% increase. Management then raised its 2026 adjusted EBITDA outlook to a range of $5.05 billion to $5.20 billion, lifting the midpoint by $195 million. The quarter's adjusted EBITDA included a $147 million favorable impact from transition-related items, so not all of that strength will recur. Still, the core beat and the higher guidance gave investors a solid fundamental base to buy into once the policy backdrop improved.
What is the Tenet Healthcare Corporation Rating - Should I Buy?
Weiss Ratings assigns THC a B rating. Current recommendation is Buy. That rating reflects a company firing on nearly every fundamental cylinder, with four of five sub-indices rated Excellent and only the Volatility Index holding the profile back from the A range.
The Excellent rating on the Growth Index rests on steady, profitable expansion. Revenue growth of 6.47% matches the 6.5% top-line gain in the latest quarter, and earnings are growing far faster than sales, with Q3 adjusted EPS up nearly 80% year over year. The Efficiency Index is also rated Excellent, supported by a 41.70% return on equity. That is an exceptional figure for a hospital and surgical operator in a labor-intensive, reimbursement-dependent industry. A 13.08% profit margin points the same way: the shift toward higher-margin ambulatory surgery is showing up in results. The Excellent Solvency Index rating shows a balance sheet strong enough to fund that strategy without strain. The Excellent Total Return Index rating reflects what shareholders have actually experienced, a stock now trading above its prior 52-week high. Even after that run, a forward P/E of 7.73 against trailing EPS of $34.48 means the valuation has not caught up with the earnings power.
Where the picture becomes more nuanced is volatility. The Fair rating on the Volatility Index captures how sensitive Tenet is to Washington. Today's 8.28% jump on the midterm results shows how quickly policy headlines can move the shares, in either direction. Hospital operators live and die by Medicaid and ACA enrollment trends, and that exposure keeps the Volatility Index from being rated higher even as every other dimension rates at the top of the scale.
Within the Health Care sector, Tenet is on par with McKesson Corporation (MCK, B) and Cencora, Inc. (COR, B). It ranks ahead of its closest hospital peer, HCA Healthcare, Inc. (HCA, B-), as well as Medtronic plc (MDT, B-). Cardinal Health, Inc. (CAH, B+) holds a slight edge, but Tenet's combination of Excellent fundamentals and a single-digit forward multiple makes it one of the more compelling names in the group.
About Tenet Healthcare Corporation
Tenet Healthcare Corporation (THC) is a Dallas-based Health Care company that runs a diversified network of acute care hospitals, ambulatory surgery centers, surgical hospitals, and related outpatient facilities across the United States. Its hospital operations provide inpatient and outpatient care, emergency services, surgery, and specialty care in the communities it serves. These facilities form the foundation of a business built around serving insured, Medicare, and Medicaid patient populations in key regional markets.
The crown jewel of the portfolio is United Surgical Partners International (USPI), one of the largest ambulatory surgery platforms in the country. USPI operates surgery centers and surgical hospitals that perform procedures such as orthopedic, spine, and gastrointestinal surgeries in lower-cost outpatient settings. Payers and patients increasingly favor that model, and it carries structurally higher margins than traditional inpatient care. Tenet has steadily reshaped its portfolio toward this ambulatory segment, which has become a primary engine of earnings growth.
Tenet also operates Conifer Health Solutions, which provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, and employers. The mix of a scaled hospital footprint, a market-leading ambulatory surgery network, and a services arm gives Tenet several distinct revenue streams. Its deep relationships with physicians and payers in its markets create competitive advantages that newer entrants cannot easily replicate.
Investor Outlook
Tenet Healthcare Corporation (THC) carries a Weiss Rating of B (Buy). Today's policy-driven breakout above $283.05 adds momentum to a story already supported by a raised EBITDA outlook and a forward P/E under 8. Investors should watch how the new Congress handles the One Big Beautiful Bill's Medicaid provisions and ACA subsidy extensions, along with whether Tenet's Q4 results confirm its $5.05 billion to $5.20 billion EBITDA guidance once the one-time transition benefits fall away. See full rankings of all B-rated Health Care stocks inside the Weiss Stock Screener.
--